DEC 04, 2019 8:01 AM PST

Genetic platform takes the guesswork out of catching infections

WRITTEN BY: Tara Fernandez

A physician is faced with 3 patients: an elderly person with a chronic cough, a child being wheeled out of surgery and a young mother with a high fever. How does the doctor identify which of these patients needs antibiotics? The answer: mostly guesswork. And, more than likely, all 3 will be prescribed with a course of antibiotics.

The problem, as described by physician turned entrepreneur Tim Sweeney, lies in the fact that we don’t have a way of accurately detecting the early stages of bacterial or viral infections. While hospitals routinely use blood tests, the majority of pathogenic infections are, in fact, not detectable in the blood circulation. To play it safe, physicians often administer antibiotics as a precautionary measure, especially considering the drug-free alternative could mean an elevated risk of sepsis.

During sepsis, an extreme inflammatory response floods the body with chemicals to fight the infection. This process can snowball, triggering dangerous and potentially life-threatening chemical imbalances, culminating in irreversible damage to multiple organ systems. Sepsis represents a major clinical crisis, responsible for half of all deaths in hospital and is the most expensive diagnosis in the US healthcare system.

The unconstrained use of antibiotics, however, is not the answer. Not only do these drugs pose significant side effects to patients, but they also contribute to a serious global epidemic: the steady rise of the antibiotic-resistant superbug.

Sweeney, together with a team of computational immunologists at Stanford University envisioned a future where doctors had access to robust diagnostic tools to check for the early signs of infections, leaving the guesswork out of the equation. 

Using machine learning methods, they analyzed the genetic activation signatures of multiple cohorts of patients around the world. This technique, called transcriptomic analysis, enabled them to draw out definitive patterns of activation in genes that control inflammation, in patients with bacterial and viral infections. 

Fascinatingly, the team discovered specific genetic motifs unique to patients at risk of sepsis. Analyzing a cluster of just 7 genes gave the researchers enough information on the presence and severity of the infection, even highlighting whether it is bacterial or viral in nature.

Expanding this to a set of 30 genes increased the granularity of the diagnosis, including what type of treatment would be most effective, downstream diagnostic tests to run and whether or not the individual needs urgent emergency care. All this in under 30 minutes.

This innovation has been commercialized by the start-up company Inflammatix, of which Sweeny is a co-founder. Inflammatix has been creating a buzz recently after getting a $6 million funding injection from the Biomedical Advanced Research and Development Authority (BARDA) to further develop its platform for diagnosing both sepsis and influenza. 

If all goes well, the deal has the potential to be worth up to $72 million - a relatively small price for the lifesaving potential of this technology.


Sources: Inflammatix, TEDx Talks

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
JAN 21, 2020
Clinical & Molecular DX
Brain scans of teens predict their risk of binge drinking
JAN 21, 2020
Brain scans of teens predict their risk of binge drinking
We’ve seen teenage binge drinking widely represented in popular culture. There is, however, a dark side to what ma ...
JAN 30, 2020
Genetics & Genomics
How To Choose The Right DNA Testing Kit For You
JAN 30, 2020
How To Choose The Right DNA Testing Kit For You
One of the most exciting scientific advancements in the past decade, at least in terms of its impact on pop culture, was ...
FEB 07, 2020
Clinical & Molecular DX
New diagnostic technology uses levitating proteins
FEB 07, 2020
New diagnostic technology uses levitating proteins
Intrinsic biophysical properties of proteins hold valuable clues about how they function and their role in disease. Take ...
FEB 26, 2020
Clinical & Molecular DX
Is your kid's stomach ache from appendicitis? Probably not.
FEB 26, 2020
Is your kid's stomach ache from appendicitis? Probably not.
Complaints about a painful belly are a common childhood lament. In such situations, the first thing that often comes to ...
MAR 12, 2020
Clinical & Molecular DX
Molecular biomarker in saliva predicts childhood obesity
MAR 12, 2020
Molecular biomarker in saliva predicts childhood obesity
Epigenetic changes modify how genes are switched on and off, without altering DNA’s genetic code sequence. These e ...
APR 23, 2020
Clinical & Molecular DX
FDA Approves At-Home Sample Collection Diagnostic Test for COVID-19
APR 23, 2020
FDA Approves At-Home Sample Collection Diagnostic Test for COVID-19
The coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). M ...
Loading Comments...